Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C

COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.

"Physicians are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates or reducing side effects and making treatment more tolerable for their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "We undertook these large PEGINTRON studies to help investigators address these important clinical issues. Conducting these studies demonstrates Schering-Plough's longstanding commitment to investigating potential new treatment strategies for patients with hepatitis C."

Combination therapy with peginterferon and ribavirin is a recognized standard of care worldwide for treating chronic hepatitis C virus (HCV) infection. Patients with HCV genotype 1, the most common and hardest to treat form of hepatitis C, are typically treated for 48 weeks, while patients with HCV genotypes 2 or 3 are treated for 24 weeks.

The aim of the three PEGINTRON studies was to evaluate investigational regimens in these patient populations compared to current standard practice.

Key Findings

PEGINTRON Maintenance Therapy in Cirrhotic (Metavir F4) HCV Patients Who Failed to Respond to Interferon
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "12th Annual ... Production" report to their offering. ... Biopharmaceutical Manufacturing Capacity and Production is the most ... organizations, current and projected future capacity and production. ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Findings indicate early non-responders unlikely to subsequently,respond, ... benefit,from earlier change in treatment strategy, COLORADO ... data presented at the 2007 International Congress ... be assessed earlier than is presently thought, ...
... Average of More Than Two Hours Per ... 2007 /PRNewswire/ --,Adding the once daily, investigational ... to,Parkinson's patients' existing levodopa (L-dopa) therapy,significantly reduced ... activities for a longer period of time. ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:8/29/2015)... ... 2015 , ... Rio Salado College President Chris Bustamante announced on ... of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the ... and impact through innovative technologies and strategies. , “I am very proud to be ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining ... County Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage ... their outpatient wound center. , Transitioning wound care management providers can be ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... that the Bihar Government would do all that it ... the state //, addressing a HIV/AIDS workshop, organized by ... Control Organization (NACO). ,Expressing concern over the ... the Minster highlighted the need for concerted efforts in ...
... take a deep breath, immediately exhale forcefully and then ... before takeoff. // ,That is the advice ... German initials BVDP), which said the technique relaxes muscles ... ,BVDP chairwoman Christa Roth-Sackenheim advised affected persons to refrain ...
... which are used for calming the nervous, can ... older people. // ,Substances like diphenhydramine, ... create this paradox, says Ursula Sellerberg, spokeswoman for ... in Berlin. ,Diazepam, the main ingredient ...
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... Organization is beginning a five-day nationwide polio immunization campaign in ... children, below the age of five. // ,The ... said, "In fact, we are seeing that the number of ... even feel that in the North of the country which ...
... A research team from Georgia Institute of Technology has ... triposphate (ATP) release and its role in cystic fibrosis. ... micro- and nano-electrodes to the tip of an atomic ... simultaneously monitor topography along with electrochemical activity at the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3
All purpose, low profile punches with a large square bite....
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... combines solutions for basic requirements with ... diagnostics, integration of the entire digital ... microscope into the hospital's information and ... OR staff.,OPMI Pentero is the first ...
Medicine Products: